/
RPRX
$56.38-$0.71 (-1.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$24.9B
443M shares
52-week range
$34.08 – $57.22
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$14.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $392.6M | $83.0M | $26.3M | $200.1M | $177.1M | $52.0M | $2.0M | $452.0M |
| Operating income | $1.36B | $2.62B | $1.60B | $1.43B | $307.1M | $1.49B | $1.29B | $1.56B |
| EBITDA | $1.83B | $2.75B | $1.88B | $1.43B | $423.7M | $1.89B | $1.56B | $1.64B |
| Net income | $1.38B | $2.35B | $975.0M | $619.7M | $42.8M | $1.13B | $859.0M | $770.9M |
| Net margin | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| EPS (diluted) | 3.89 | 6.63 | 1.28 | 1.49 | 0.10 | 2.53 | 1.91 | 1.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.5B | $5.13 | $4.69–$5.33 | 4 |
| 2027 | $3.7B | $5.62 | $5.30–$5.97 | 5 |
| 2028 | $4.0B | $6.28 | $4.24–$8.33 | 2 |
| 2029 | $4.6B | $7.04 | $6.86–$7.21 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$25.69
Price
$56.38
Implied downside
-54%
Peer comparison
Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
www.royaltypharma.com- Employees
- 100
- IPO / List date
- Jun 16, 2020
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds RPRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RPRX as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.61% ($0.91/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-15 | $0.2350 | 2026-06-10 |
| 2026-02-20 | $0.2350 | 2026-03-10 |
| 2025-11-14 | $0.2200 | 2025-12-10 |
| 2025-08-15 | $0.2200 | 2025-09-10 |
| 2025-05-16 | $0.2200 | 2025-06-10 |
| 2025-02-21 | $0.2200 | 2025-03-10 |
| 2024-11-15 | $0.2100 | 2024-12-10 |
| 2024-08-16 | $0.2100 | 2024-09-13 |
| 2024-05-16 | $0.2100 | 2024-06-14 |
| 2024-02-15 | $0.2100 | 2024-03-15 |
Recent trades on TradeandTell
No one on the platform has traded RPRX yet.
